Trial · NCT00288015

Bevacizumab in Treating Patients With Angiosarcoma

NCT00288015, Phase 2, Completed, Northwestern University; results first posted 2018-06-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Bevacizumab in Treating Patients With Angiosarcoma. Trials, record NCT00288015. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00288015

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Bevacizumab in Treating Patients With Angiosarcoma
NCT number: NCT00288015
Status: Completed
Phases: Phase 2
Enrollment: 32 participants, actual
Lead sponsor: Northwestern University
Conditions: Sarcoma
Interventions: Bevacizumab
First posted: 2006-02-07
Last updated: 2018-06-25
Results first posted: 2018-06-25

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria.	After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years.	During treatment, tumor assessment was done by MRI scan after the second cycle of study treatment, after the forth cycle of study treatment, and then every 3 cycles of treatment thereafter. After Study drug completion, tumor assessment by MRI was done every 3 to 4 months (for up to 2 years after the last bevacizumab dosage). Responses were categorized according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
Secondary	Objective Response Rate in Patients Treated With Bevacizumab.	After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years.	Objective response rate will be measured per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Stable Disease, neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study. Progressive Disease, defined as having at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.
Secondary	Duration of Response.	After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years.	During treatment, evaluation of response will be done by MRI scan after the second cycle of study treatment, after the forth cycle of study treatment, and then every 3 cycles of treatment. After Study drug completion, evaluation of response will be assessed by MRI every 3 to 4 months (for 2 years after the last bevacizumab dosage).
Secondary	Assess the Treatment Effect of Bevacizumab on Duration of Overall Survival	After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years	After Study drug completion, assessment of treatment effect of bevacizumab on duration of overall survival will be assessed by MRI every 3 to 4 months (for 2 years after the last bevacizumab dosage).
Secondary	Evaluate the Toxicity of Bevacizumab.	Day 1 of every cycle, on average every 21 days until end of treatment up to 2 years.	Toxicity data for bevacizumab will be collected on day 1 of every cycle (1 cycle = 21 days) during treatment according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0). In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria.	After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years.		Weeks	MEDIAN
SECONDARY	Objective Response Rate in Patients Treated With Bevacizumab.	After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years.		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Duration of Response.	After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years.	Data for this outcome measure was not collected. By the time the results of the study were being collected, this outcome measure was no longer relevant as Recist 1.0 was in use. As a result, data for this outcome measure was not collected or analysed. Time to progression was a more relevant data point.
SECONDARY	Assess the Treatment Effect of Bevacizumab on Duration of Overall Survival	After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); every 3-4 months after treatment up to 2 years		Weeks	MEDIAN
SECONDARY	Evaluate the Toxicity of Bevacizumab.	Day 1 of every cycle, on average every 21 days until end of treatment up to 2 years.	Number of participants with either grade 1 (mild), 2 (moderate),3 (severe), 4 (life-threatening) adverse event related to treatment.	participants	NUMBER
POST_HOC	Time to Progression	After cycles 2 and 4, then every 3 cycles thereafter while on treatment (1 cycle = 21 days); ever 3-4 months after treatment up to 2 years		Weeks	MEAN

Source ClinicalTrials.gov

Results by group29

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria.	Bevacizumab		12.4	95% Confidence Interval 10.1 to 14.76	Weeks
Objective Response Rate in Patients Treated With Bevacizumab.	Bevacizumab	Partial response	4		Participants
Objective Response Rate in Patients Treated With Bevacizumab.	Bevacizumab	Stable disease	15		Participants
Objective Response Rate in Patients Treated With Bevacizumab.	Bevacizumab	Progressive disease	11		Participants
Assess the Treatment Effect of Bevacizumab on Duration of Overall Survival	Bevacizumab		107	95% Confidence Interval 44.29 to 169.99	Weeks
Evaluate the Toxicity of Bevacizumab.	Bevacizumab	Participants with one bevacizumab related event	26		participants
Evaluate the Toxicity of Bevacizumab.	Bevacizumab	Thromboyctopenia	4		participants
Evaluate the Toxicity of Bevacizumab.	Bevacizumab	Shortness of breath	5		participants
Evaluate the Toxicity of Bevacizumab.	Bevacizumab	Hypertension	7		participants
Evaluate the Toxicity of Bevacizumab.	Bevacizumab	Pain	3		participants

1 to 10 of 29Source ClinicalTrials.gov

See all 29 results by group

Participant flow15

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Registered to Study	STARTED	Bevacizumab	32
Registered to Study	COMPLETED	Bevacizumab	32
Registered to Study	NOT COMPLETED	Bevacizumab	0
Bevacizumab Treatment Cycles 1-2	STARTED	Bevacizumab	32
Bevacizumab Treatment Cycles 1-2	COMPLETED	Bevacizumab	30
Bevacizumab Treatment Cycles 1-2	NOT COMPLETED	Bevacizumab	2
First Response Assessment	STARTED	Bevacizumab	30
First Response Assessment	COMPLETED	Bevacizumab	26
First Response Assessment	NOT COMPLETED	Bevacizumab	4
Continued Bevacizumab Cycle 3+	STARTED	Bevacizumab	26

1 to 10 of 15Source ClinicalTrials.gov

See all 15 participant flow

Adverse events83

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Fatigue	General disorders	Bevacizumab	17	30	23
other	Headache	Nervous system disorders	Bevacizumab	10	30	18
other	Hemoglobin (anemia)	Blood and lymphatic system disorders	Bevacizumab	9	30	16
other	Leukocytes (total white blood cells)	Blood and lymphatic system disorders	Bevacizumab	5	30	10
other	Lymphopenia	Blood and lymphatic system disorders	Bevacizumab	2	30	2
other	Platelet decrease	Blood and lymphatic system disorders	Bevacizumab	7	30	16
other	hypertension	Cardiac disorders	Bevacizumab	15	30	24
other	Palpitations	Cardiac disorders	Bevacizumab	1	30	1
other	Supraventricular and nodal arrhythmia- atrial fibrillation	Cardiac disorders	Bevacizumab	2	30	2
other	Fever	General disorders	Bevacizumab	4	30	4

1 to 10 of 83Source ClinicalTrials.gov

See all 83 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Bevacizumab	14	30
Total, other adverse events	Bevacizumab	30	30
Total, serious adverse events	Bevacizumab	8	30

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00288015

GET https://conductscience.org/api/trials/v1/NCT00288015/results?page=2

API reference For AI assistants